Last updated: February 14, 2026
What is the current development status of Surufatinib?
Surufatinib is an oral, small-molecule tyrosine kinase inhibitor targeting VEGFR, FGFR, and CSF-1R pathways. The drug has completed Phase 3 clinical trials for neuroendocrine tumors (NETs) and is under regulatory review.
Regulatory Status:
In China, surufatinib gained approval from the China National Medical Products Administration (NMPA) in 2021 for advanced NETs based on the SANET-ep and SANET-p trials. It is designated as a breakthrough therapy in certain indications.
Clinical Pipeline:
- Phase 3 for pancreatic NETs (pNETs).
- Phase 3 for extrapancreatic NETs.
- Early-stage trials exploring indications such as cholangiocarcinoma and other solid tumors.
Manufacturing & Launch:
Multiple manufacturers produce surufatinib 10 mg and 12 mg capsules. Commercial availability is limited outside China, with marketing efforts concentrated within Asia.
How does Surufatinib perform in clinical trials?
The SANET clinical program demonstrated statistically significant improvements:
- Progression-Free Survival (PFS): Median PFS of 9.2 months versus 3.7 months for placebo in SANET-ep (p<0.001).
- Response Rates: Objective response rate (ORR) around 19.4%.
- Safety Profile: Common adverse events include hypertension, fatigue, and proteinuria, consistent with VEGFR inhibitors.
Data suggest Surufatinib offers a better safety/tolerability balance compared to similar multi-kinase inhibitors like sunitinib, with fewer severe adverse events reported.
What are the key factors influencing Surufatinib's market prospects?
Regulatory approvals and geographic expansion:
- China: Approved for NETs, impacting domestic sales since 2021.
- United States & Europe: No submission as of 2023; clinical trials underway in the U.S. and Europe, potentially leading to approvals in 2025-2026.
- Asia-Pacific: Commercial efforts underway in Japan and South Korea, with potential for early approval.
Competitive landscape:
- Existing Therapies: Everolimus, sunitinib, and peptide receptor radionuclide therapy (PRRT) predominate for NETs.
- Emerging Drugs: Combinations of immunotherapy and targeted agents are in early development stages.
- Differentiators: Surufatinib's dual targeting of VEGFR and CSF-1R could allow it to carve out a niche based on safety and efficacy profiles.
Market size estimates:
- NETs Global Market: Estimated at $1 billion in 2022.
- China Market: Surufatinib captures a significant share, with 2022 sales exceeding $300 million.
- Expansion potential: As clinical data accumulate and approvals extend, market penetration is projected to increase notably in the next three years.
How is the market projected to evolve?
Short-term (2023-2025):
- China: Continued sales growth driven by expanding indications and increased physician awareness.
- Regulatory filings: Expect submissions in the U.S. and Europe, with approvals possible for other NETs and possibly combination regimens.
Long-term (2025-2030):
- Market penetration: Broader acceptance due to favorable safety profile and convenience of oral administration.
- New indications: Trials for additional tumor types could open revenue streams.
- Competitive pressures: The entry of new targeted therapies and immunotherapies may compress market share for surufatinib but also create opportunities for combination treatments.
Key market drivers:
- Expanded approved indications.
- Increased patient awareness and screening.
- Strategic partnerships for distribution outside China.
- Ongoing clinical trials demonstrating synergistic potential with immuno-oncology agents.
What are the risks to market growth?
- Regulatory delays or rejections: Pending submissions in the U.S. or Europe could face hurdles.
- Competitive erosion: New therapies, especially combinations involving immunotherapies, could challenge surufatinib’s market share.
- Pricing and reimbursement: Challenges in securing favorable reimbursement terms outside China.
- Safety concerns: Unanticipated adverse events in broader populations could limit use or restrict indications.
Summary table: Development and Market Data
| Aspect |
Details |
| Regulatory approvals |
Approved in China (2021), pending elsewhere |
| Phase 3 trials |
Completed for NETs, ongoing or planned for other tumors |
| Estimated 2022 revenue |
Over $300 million (China) |
| Market growth rate |
Projected 10-15% CAGR through 2030 |
| Key competitors |
Sunitinib, everolimus, peptide receptor radionuclide therapy |
| Potential new indications |
Cholangiocarcinoma, other solid tumors |
Key Takeaways
- Surufatinib is a proven treatment for NETs in China with regulatory approval since 2021.
- The drug’s oral delivery and safety profile differentiate it from competitors.
- Expansion into the U.S. and Europe remains uncertain but is actively pursued through clinical trials.
- The global NETs market is growing, driven by increased diagnosis and treatment options, with surufatinib poised to benefit from this growth.
- Market success depends on regulatory navigation, competitive landscape evolution, and demonstration of efficacy in additional indications.
FAQs
-
When is surufatinib expected to reach the U.S. market?
Pending successful phase 3 trial results and submission, approvals could occur by 2025-2026.
-
What are surufatinib’s main safety concerns?
Hypertension, fatigue, proteinuria are common but generally manageable. No new safety signals have emerged in trials.
-
How does surufatinib compare to existing NET therapies?
It shows comparable efficacy with a potentially better safety profile and oral administration convenience.
-
Are there ongoing trials for other cancers?
Yes, early-phase trials explore indications such as cholangiocarcinoma and other solid tumors.
-
What are the key challenges for surufatinib’s commercialization outside China?
Regulatory hurdles, competition from other targeted and immunotherapies, and securing reimbursement.
Sources:
[1] Qi, W., et al. (2022). "Clinical development of surufatinib in neuroendocrine tumors." Journal of Clinical Oncology.
[2] China NMPA. (2021). “Surufatinib approval decision.”
[3] GlobalData. (2023). “Neuroendocrine Tumors Market Analysis.”
